Novo Nordisk A/S: Trading In Novo Nordisk Shares By Board Members, Executives And Associated Persons

(MENAFN- GlobeNewsWire - Nasdaq)

Trading in Novo Nordisk shares by board members, executives and ass ociated persons

Bagsværd , Denmark, 5 August 202 2 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Kasim Kutay
2 Reason for the notification
a) Position/status Member of the Board of Directors
b) Initial notification/Amendment Initial notification
3 Details of the issuer
a) Name Novo Nordisk A/S
b) LEI 549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a) Description of the financial instrument,
type of instrument,
Identification code NVO
b) Nature of the transaction Purchase of ADRs

Price(s) and volume(s)

Price(s) Volume(s)
DKK 758.55 116 ADRs
d) Aggregated information
  • Aggregated volume
  • Price

116 ADRs
DKK 758.55
e) Date of the transaction 2022-08-04
f) Place of the transaction New York Stock Exchange

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit , Facebook , Twitter , LinkedIn , and YouTube .

Further information

Ambre Brown Morley +45 3079 9289
Natalia Salomao Abrahao (US) +1 848 304 1027
Daniel Muusmann Bohsen +45 3075 2175
Ann Søndermølle Rendbæk +45 3075 2253
David Heiberg Landsted +45 3077 6915
Jacob Martin Wiborg Rode +45 3075 5956
Mark Joseph Root (US) +1 848 213 3219

Company announcement No 63 / 2022


  • CA220805_InsiderTrading

Attachments CA220805_InsiderTrading...


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.